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ABSTRACT: Replication protein A (RPA) is the major human single stranded DNA (ssDNA)-binding protein, playing essential 
roles in DNA replication, repair, recombination and the DNA-damage response (DDR). Inhibition of RPA-DNA interactions repre-
sents a therapeutic strategy for cancer drug discovery and has great potential to provide single agent anticancer activity and to syner-
gize with both common DNA damaging chemotherapeutics 
and newer targeted anticancer agents. In this letter, a new 
series of analogues based on our previously reported TDRL-
551 (4) compound were designed to improve potency and 
physicochemical properties. Molecular docking studies 
guided molecular insights and further SAR exploration led 
to the identification of a series of novel compounds with low 
micromolar RPA inhibitory activity, increased solubility and 
excellent cellular up-take. Among a series of analogues, 
compound 43, 44, 45 and 46 hold promise for further development of novel anti-cancer agents. 
The clinical efficacy of many DNA damaging cancer 
chemotherapeutics involves inducing DNA damage to push 
cancer cells into apoptosis.1-2 DNA damage is repaired by in-
trinsic repair pathways and is coordinated by the DNA damage 
response (DDR) pathway. One mechanism to enhance the ther-
apeutic window associated with these therapies is to direct treat-
ment to those cancers that harbor intrinsic DNA repair deficien-
cies.3-5 This approach has been effectively exploited in synthetic 
lethal strategies to develop safe and effective treatments.1 With 
an appropriately selected drug target, there is the potential to 
enhance both single agent activity and synergistic anti-cancer 
effect of the same chemical entity. Therefore, targeting DNA 
repair and the DDR deficiencies has the potential for more 
selective, better tolerated therapies to improve cancer pa-
tient survival.6-7  
Replication protein A (RPA) is the major human ssDNA 
binding protein and plays an integral role in both nucleotide ex-
cision repair (NER) and homologous recombination (HR) DNA 
repair pathways in addition to its essential role in DNA replica-
tion and DDR.8-10 Each of these critical roles of RPA make the 
RPA-DNA interaction a promising target to develop novel anti-
cancer therapeutics. RPA is also overexpressed in a number of 
cancers including lung, ovarian, breast, colon and esophageal11-
12 One rationale for targeting RPA is based on RPA exhaustion 
which can lead to replication catastrophe.  By extension, one 
can envision that cancer cells exhibiting replication stress re-
quire more RPA for survival compared to non-cancer cells to 
provide a therapeutic treatment window.
Over the past few years, several RPA inhibitors have been 
identified and have either focusing on blocking the protein-pro-
tein13,15-22 or the protein-DNA interaction14,23-26 (Figure 1A).  
Targeting the F-domain has proven effective for disrupting pro-
tein-protein interactions and the A and B domains of RPA70 for 
protein-DNA inhibitors.27-29 Previously, we have successfully 
discovered and developed compounds 1-4 which block the 
RPA-DNA interaction.23-26 Particularly, compound 3 (TDRL-
505) and 4 (TDRL-551) display single agent activity in lung and
ovarian cancer cell lines and also synergize with cisplatin and
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Figure 1. A) Structure of previously reported RPA inhibitors targeting RPA-DNA interaction.23-26 B) Schematic representation of SAR 
design rationale: a large space-filling pocket surrounding Ring A of compound 4 and amino acid residues surrounding alkyl carboxylic acid 
side chain which can be extended towards the solvent-exposed region for further structural optimization. [Compound 4 hydrogen bond 
interaction with Ser392 and Arg382 is indicated with the dashed magenta line, π-π stacking interactions with Trp361 and Phe386 are shown 
in solid magenta dumbbell, and salt-bridge interactions with Lys313 are shown in dashed two-sided magenta arrow.]  
etoposide.25-26  The mechanism of action of both compounds is 
via a reversible interaction with the central OB-folds in DNA 
binding domains A and B of RPA70. In vivo analysis of com-
pound 4 (TDRL-551) revealed minimal cytotoxicity alone and 
in combination with platinum was able to significantly delay 
tumor growth in a NSCLC xenograft model.26  Both compounds 
3 and 4, however, had limited solubility and cell permeability. 
In this Letter, we further expanded our structure-guided drug 
design efforts by exploiting compound 4 (TDRL-551) scaffold 
with the aim to improve RPA inhibitory potency, solubility and 
cellular uptake. 
Initial molecular docking studies with compounds 3 and 4 
revealed that both compounds have a high predicted affinity for 
DNA binding domain B. We performed molecular docking 
studies mainly focusing on the central DNA binding domains A 
and B of RPA70 by using RPA70181-422 X-ray crystal structure 
(PDB code: 1FGU).29 The interaction presented in the Figure 
1B reveals the stability is driven via hydrophobic and π-π inter-
actions, and that the conserved alkyl carboxylic acid side chain 
is stabilized via interactions with basic amino acid residues 
which are critical for inhibitory activity. In addition, docking 
studies revealed the extended terminal carboxylic acid side 
chain appeared to orient towards the solvent-exposed region of 
the protein and provides a potential site for modulating the 
physicochemical properties of these compounds. We have ex-
ploited compound 4’s interaction with domain B to outline a 
SAR design for further structural optimization (Figure 1B). We 
first pursued optimizing aromatic Ring A exploiting the large 
pocket around it and also simultaneously optimizing alkyl car-
boxylic acid side chain to improve the drug-like properties.  
The synthesis of target compound 4 and its analogs 16-25 is 
depicted in Scheme 1. We have obtained compound 4 and 16-
25 from starting material 3-ethoxyaniline by slightly modifying 
our previous synthetic protocol.26  The requisite quinoline 
carbaldehyde 6 was prepared by acylation of 3-ethoxyaniline 
with acetic anhydride, followed by multicomponent reaction 
that involves process of Vilsmeier-Haack chlorination, 
formylation and cyclization of acetanilide using DMF and 
POCl3. Claisen-Schmidt condensation of corresponding substi-
tuted acetophenones 7-10 with quinoline carbaldehyde 6 in the 
presence of aqueous NaOH in ethanol yielded corresponding 
1,3-diarypropenones 11-14 which on further treatment with hy-
drazine hydrate in ethanol under reflux afforded the correspond-
ing 2-pyrazolines 15a-d in good yields.  Compound 4 and 16-
18 were obtained in good yields by acylation at N1 of the pyra-
zoline ring of compounds 15a-d with glutaric anhydride in 
chloroform. Upon reduction of nitro group of 18 by stannous 
chloride, the desired amine product 19 was obtained in an ac-
ceptable yield. The synthesis of compound 20 and 21 was ac-
complished by acylation of hydroxyl group of compound 17 us-
ing acryloyl chloride and morpholinecarbonyl chloride, respec-
tively, in basic condition. To further extend the substitution on 
para-position at ring A, we have synthesized target compounds 
22-29 as depicted in Scheme 1 and supplemental Scheme S1. 
Compound 30 was prepared from an above synthesized precur-
sor 15a by N1-acylation of the pyrazoline ring using ethyl glu-
taryl chloride in basic condition. Intermediates 31a-d were pre-
pared by optimizing Pd-catalyzed Suzuki coupling of com-
pound 30 with corresponding boronic acids/esters using non-
aqueous CsF in dimethoxyethane protocol. Final target com-
pounds 22-25 were obtained from compounds 31a-d by hydrol-
ysis of corresponding alkyl esters using 10N NaOH at room 
temperature. Our initial attempt utilizing Scheme 1 to synthe-
size halopyridine containing compounds 26-28 had limited ef-
ficiency as a function of the late stage Suzuki coupling reaction.  
Therefore, we have achieved efficient synthesis of target com-
pounds 26-29 as outlined in Supplemental Scheme S1. Early 
stage Suzuki coupling of 4′-iodoacetophenone 7 with commer-
cially available boronic acids/esters 32a-d catalyzed by 
tetrakis(triphenylphosphine)palladium(0) in the presence of 
aqueous potassium carbonate base provided precursors 33a-d. 
1,3-diarypropenones 34a-d were synthesized using an above 
described Claisen-Schmidt condensation of corresponding sub-
stituted methyl ketones 33a-d with quinoline carbaldehyde 6 
then 1,3-diarypropenones 34a-d refluxed with hydrazine hy-
drate in ethanol to afford corresponding 2-pyrazolines 35a-d in 
good yields. Finally, acylation at N1 of the pyrazoline ring of 
compounds 35a-d with glutaric anhydride in chloroform under 
reflux provided target compounds 26-29 in moderate to good 
yields after recrystallization in ethanol.   
To optimize the alkyl carboxylic acid side chain of compound 
4, we have synthesized compounds 37-47 as depicted in Sup-
plemental Schemes S2 and S3. The N1-acylation of the pyra-
zoline ring of precursor 15a using alkyl acyl chloride in basic  
conditions afforded ester derivatives 36a-b and subsequent es-
ter hydrolysis using NaOH, provided analogs 37-38 in excellent 
yields (Supplemental Scheme S2).   To introduce rigidity in the 
RPA binding pocket, we have synthesized compounds 39-40 
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Scheme 1. Synthesis of Compound 4 and Analogs 16-25a 
 
aReagents and conditions: (a) acetic anhydride, DIPEA, DMAP, DCM, rt for 2 h, 88%; (b) (i) DMF, POCl3, 0°C for 25 min, (ii) acetanilide 
5, 110°C for 3 h, 74%; (c) 2.5M NaOH, EtOH, 45°C for 45 min to 1 hr, 53-74%; (d) hydrazine hydrate, EtOH, reflux for 2-3 h, 70-83%; (e) 
glutaric anhydride, CHCl3, reflux for 2 h, 58-71% (after recrystallization); (f) SnCl2, EtOH:THF (1:1), reflux for 2 h, 48% (after recrystalli-
zation); (g) acryloyl chloride, 2N NaOH, THF, 0°C to rt for 2 h, 34%; (h) 4-morpholinecarbonyl chloride, TEA, DMAP, THF, 0°C to rt for 
12 h, 63%.  (i) ethyl glutaryl chloride, DIPEA, DCM, rt for 12 h, 78%; (j) boronic acid/ester, Pd(PPh3)4, CsF, DME, 90°C for 15-18 h, 63-
69%; (k) 10N NaOH, THF:MeOH (1:2), rt for 6-8 h, 75-87%. 
from precursor 11 and using corresponding substituted hydra-
zinobenzoic acid under reflux condition in AcOH and n-buta-
nol. Furthermore, the morpholine/morpholinoalkylamine 
group was attached to the oxopentanoic acid side chain of cor-
responding compound 4 or 16 or 26 or 28 or 29 by utilizing 
EDCI/HOBt amide synthetic protocol to achieve final com-
pounds 41-47 in good yields (Supplemental Scheme S3).  
The assessment of RPA inhibitory activity was performed 
using a highly sensitive and quantitative electrophoretic mo-
bility shift assay (EMSA).  The assay employs purified het-
erotrimeric human RPA devoid of any tags or modifications 
and measures the impact of the compounds on direct RPA 
binding to a ss-DNA substrate.23,26,30 We also have confirmed 
that the compounds specifically target OB-folds A and B  us-
ing an RPA construct consisting of this minimal DNA binding 
domain (See Supplemental Table S2), as we have previously 
described.25 RPA can also interact with damage duplex DNA 
via binding to the undamaged ssDNA regions opposite the 
damage.30  The RPA inhibitory compounds also, as expected, 
block this interaction.  For the purpose of quantifying RPA 
inhibitory activity we used gold-standard, full length RPA 
binding to single stranded DNA to calculated IC50 values of 
newly synthesized analogs and provide insight into the struc-
ture-activity relationships (Table 1 and 2).  The replacement 
of the iodo group of compound 4 (IC50 = 15.3 ± 1.42 μM) with 
hydroxyl or nitro groups resulted in a near complete loss of 
RPA inhibitory activity while changing to an amine resulted 
in a 7-fold increase in potency (IC50 = 2.3 ± 0.22 μM). Acry-
late containing compound 20 exhibited 2-fold increase in ac-
tivity compared to 4, surprisingly, the inclusion of mor-
pholinecarbonyl group in compound 21 resulted in poor RPA 
inhibition. Introduction of a heteroaromatic on Ring A such as 
3’-furan, 2’-furan and 4’-isoxazole boosted potency drasti-
cally as 2’-substituted furan at Ring A (compound 23, IC50 
= 2.1 ± 0.48 μM) exhibited almost 3.2-fold increase in activity 
compared to 3’-substituted furan containing compound 22 
(IC50 = 6.7 ± 0.64 μM). Insertion of another heteroatom such 
as nitrogen into the furan ring in the form of an isoxazole dis-
played even more potent RPA inhibitory activity (compound 
24, IC50 = 1.7 ± 0.28 μM). The difference in activity with the 
small changes of heteroatom within 5-membered ring may be 
due to the orientation of the ring or ability of the heteroatom 
to interact with RPA backbone binding pocket amino acid res-
idues. Further extension of compound 4 Ring A in the space-
filling binding cleft with a substituted bulky biphenyl het-
eroaromatic ring such as halogenated pyridinyl compounds 
(26-29) exhibited even more potent RPA inhibitory activities 
than parent compound with an increased potency between 4- 
and 15-fold. Among all the Ring A modifications, chloro-pyr-
idinyl compound 26 and bromo-pyridinyl compound 27 
showed the most potent RPA inhibitory activity in the EMSA 
assay (26, 1.6 ± 0.04 μM and 27, IC50 = 1.0 ± 0.60 μM). Fur-
ther, we have included fluorine and trifluoromethyl substitu-
ents in pyridinyl compounds 28-29. However, both com-
pounds displayed slightly weaker activity compared to chloro- 
and bromo-pyridinyl containing compounds 26-27. These 
data revealed the importance of bulky hydrophobic substitu-
ents on Ring A of compound 4 to occupy space-filling binding 
pocket of RPA and are consistent with our postulated molec-
ular docking binding pockets outlined in an above SAR design 
section.   
The next aim was to explore SAR on the alkyl carboxylic acid 
side chain of compound 4, with a focus on enhancing physi-
cochemical properties while retaining or improving potency. 
Modification of alkyl side chain of compound 4 revealed a 
series of interesting activity against RPA (Supplemental Ta-
ble S1). The conversion to an oxopentanoic ethyl ester (com-
pound 30) completely abrogated RPA inhibitory activity. A 
similar trend was observed with compounds 39-40 when we 
replaced oxopentanoic acids with 2’ or 3’-subsitituted ben-
zoylic carboxylic acids. The intramolecular distances between 
the benzoylic carboxylic acids and the core dihydropyrazole 
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Table 1. SAR of Ring A with RPA IC50 Values of Analogs 
16-29a  
aDetermined using EMSA, binding of full length human RPA 
to DNA was assessed. bCompounds that displayed greater than 
80% inhibition at 25 μM were analyzed in titration experiments. 
cIC50 values are a mean of minimum of triplicate independent ex-
periments and data are presented as the mean ± SD.   
 
were very similar comparing to the oxopentanoic acids.  The 
dramatic reduction in activity of the benzoylic carboxylic acid 
derivatives is likely  function on the rigidity induced restrict-
ing motion of the molecule within the RPA-DNA binding 
pocket independent of position of the carboxylic acid. Increas-
ing the length of the aliphatic side chain by 1 and 2 carbon, in 
compounds 37 and 38 respectively, had only modest effects 
on potency and similar inhibition was observed by direct ad-
dition of a N-morpholino group on alkyl carboxylic acid side 
chain depicted in compound 41 
As discussed earlier, initial docking study positioned the terminal 
carboxylic group towards the solvent-exposed region of the pro-
tein and could provide a good potential for modulating the phys-
icochemical properties of our compounds. In addition, carboxylic 
acid functional group often have limited utility in drug discovery 
due to limited passive diffusion across biological membranes 
(cellular permeability) and metabolic instability.31 Therefore, we 
articulated that RPA inhibitors could be improved by introducing 
an additional solubilizing group into the terminal carboxylic acid 
group without significantly influencing the RPA inhibitory activ-
ities. To this end, the water-soluble morpholine moiety was em-
ployed to enhance the physicochemical properties. Consistent 
with our docking analysis, replacement of the terminal carboxylic 
group with morpholinoethane (compound 42) and morpho-
linopropane (compound 43), retained the inhibitory activity while 
compound 43 showed an almost 3-fold increase in potency (IC50 
= 4.9 ± 0.28 μM) compared to our parent compound 4. Encour-
aged by these results, a series of new analogs (Table 2, com-
pounds 44-47) were further designed and synthesized by incor-
porating morpholinopropane at the terminal carboxylic group of 
compound 16, 26 and 28-29. All these compounds exhibited 
modest to potent RPA inhibitory activity compared to the parent 
compound 4 and anticipated to improve physiochemical proper-
ties for better cellular and in vivo activities.  
Table 2. SAR of Side Chain Modifications with RPA IC50 
Values of Analogs 41-47a 
 
Cpd R1 R2 RPA IC50 (μM)b,c 
41  I 
 
6.6 ± 0.48 
42 I 
 
10.5 ± 0.68 
43 I 
 
4.9 ± 0.28 
44 Br 
 
10.0 ± 1.46 
45 
  
4.0 ± 0.56 
46 
  
2.3 ± 0.31 
47 
  
5.8 ± 0.39 
 
aDetermined using EMSA, binding of full length human RPA 
to DNA was assessed. bCompounds that displayed greater than 
80% inhibition at 25 μM were analyzed in titration experiments. 
cIC50 values are a mean of minimum of triplicate independent ex-
periments and data are presented as the mean ± SD.  
To confirm the mechanism of inhibitions via compound binding 
to the target protein and not via binding to the DNA substrates, 
we conducted a fluorescent intercalator displacement (FID) assay 
as described previously.32 The displacement of a DNA binding 
dye and decrease in fluorescence is indicative of the compound’s 
Cpd R1 RPA IC50 (μM)b,c 
4 I 15.3 ± 1.42 
16 Br 19.2 ± 4.17 
17 OH >25 
18 NO2 >25 
19 NH2 2.3 ± 0.22 
20 
 






6.7 ± 0.64 
23 
 
2.1 ± 0.48 
24 
 
1.7 ± 0.28 
25 
 
3.1 ± 0.23 
26 
 
1.6 ± 0.04 
27 
 
1.0 ± 0.60 
28 
 
2.6 ± 0.60 
29 
 
4.3 ± 0.42 
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ability to bind DNA. In order to probe the potential role of DNA 
intercalation as a mechanism for RPA inhibition, most potent 
compounds 19, 23, 26, 27, 43 and 45 were  analyzed using FID 
assay along with doxorubicin (Dox) as a positive control. The re-
sults presented in Figure 2 demonstrate as expected that positive 
control, doxorubicin a known non-covalent DNA binding chemo-
therapeutic, resulted in a concentration dependent reduction in 
fluorescence. As expected, minimal DNA binding activity was 
observed for any of the novel RPA inhibitors (19, 23, 26, 27, 43 
and 45).  The slight reduction in signal cannot account for the  
             
Figure 2. Analysis of compound interactions with DNA using 
Fluorescent intercalator displacement (FID) assay. The indicated 
concentrations of doxorubicin (Dox), compounds 19, 23, 26, 27, 
43 and 45 were analyzed for the ability to displace a fluorescent 
Sybr-green DNA intercalator as a measure of compound DNA 
interactions. The data represent the average and SD of three in-
dependent experimental determinations performed in duplicates.  
high potency of the compounds.  These data suggest that the 
mechanism of action involves targeting the protein- DNA 
interaction by directly binding to the RPA protein.  Consistent 
with this conclusion is the lack of inhibitory agains other OB-fold 
containing proteins  
To delineate the key interactions and to understand the SAR 
of newly synthesized compounds, these compounds were flexibly 
docked mainly focusing on the central DNA binding domains A 
and B of RPA70 as discussed above.29 All newly developed 
inhibitors docked well at this site. Figure 3 shows the binding 
orientation and molecular interactions of representative 
compound 26, 42 and 45 within the RPA domain B region. The 
molecular interaction of 26, 42 and 45 (Figures 3A-C, 
respectively) is largely ascribed to various electrostatic 
interactions, including, i) compound 42 and 45 amide carbonyl 
make hydrogen bond contacts with the amine of Lys313, while 
compound 26 terminal carboxylic acid makes salt-bridge 
interactions with the Lys313; ii) amide carbonyl (attached to 
pyrazole ring) of all three compounds make strong hydrogen 
bond contacts with the hydroxyl group of Ser392 as well as with 
the amine group of Arg382; iii) the π – π stacking interactions 
between the phenyl moiety (Ring A) and the aromatic ring of 
Trp361 in all three compounds.  In addition, all three compounds 
quinoline moiety is also well positioned to make π – π stacking 
interactions with Phe386; iv) Terminal alkyl morpholino side 
chain is well fitted and located as its extending out of the RPA 
binding region into a solvent exposed region. Docking studies 
predicted a stronger affinity of the compound 26 than other series 
of compounds including compound 42 and 45, in fact compound 
26 also showed potent RPA inhibition than other series of 
compounds in in-vitro EMSA assay (Table 1).  
Our previous data demonstrated that compound 3 and 4 
displayed a significantly higher cellular IC50 compared to the 
biochemical in vitro IC50.25-26 This suggested cellular uptake 
could be limiting cellular activity. The charge on the carbox-
ylic acid, while potentially increasing aqueous solubility, was 
also anticipated to negatively impact cellular uptake. We 
therefore assessed aqueous solubility of a series of the most 
biochemically active compound 4 derivatives.  Figure 4A 
shows data obtained with assessing aqueous solubility in un-
buffered H2O at pH 7. The data reveal a general trend of the 
morpholino modified compounds displaying increased solu-
bility compared to their carboxylic acid counterparts (com-
pounds 4, 16, 26, 28, 29 Vs 43, 44, 45, 46, 47, respectively).  
 
Figure 3. Molecular docking studies (PDB code: 1FGU)29: A-C) 
Molecular interactions of compound 26 (A), 42 (B) and 45 (C) 
(all in yellow carbon) with hRPA (key amino acids are shown in 
dark cyan carbon and cartoon is shown in pale cyan color). 
Interaction with amino acid side chains is indicated with the 
dashed magenta lines, π – π stacking interactions are shown in 
solid magenta dumb ell and salt-bridge interactions are shown in 
dashed two-sided magenta arrow. Interaction distances indicated 
in Å. D) Molecular overlay (superimposition) of compound 26, 
42 and 45 (all in yellow carbon) in the RPA binding site. 
The cellular uptake or intracellular metabolism of the 
compounds plays an important role in cellular efficacy and it 
allows to properly rationalize structure-activity relationships 
to enhance the sustained therapeutic effect. Therefore, we 
evaluated cellular uptake of our lead compounds in H460 
NSCLC cells (Figure 4B). The data demonstrate that as ex-
pected that compound 4 has relatively poor uptake while com-
pound 26 showed increased uptake even with the carboxylic 
acid moiety. The morpholino derivative of these both com-
pounds demonstrated considerably superior uptake observed 
with the compounds 43 and 45.  We expect the increased up-
take will increase cellular RPA inhibition and anti-cancer ac-
tivity. A similar trend of increased cellular uptake was also 
observed in morpholino modified compound 46 and 47 com-
pared to their carboxylic acid counterparts (Data not shown).  
 Figure 4. Solubility analysis and cellular uptake of RPA inhibi-
tors.  A) Aqueous solubility and B) Cellular uptake of representa-
tive compounds were determined as described in the “Supporting 
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Information”. Individual data points are plotted and bars repre-
sent the mean and SD of three independent experimental deter-
minations. 
In conclusion, we have extended SAR study of our previ-
ously reported RPA inhibitor by utilizing a structure-based 
drug design strategy. We have identified a series of novel 
chemical inhibitors that interact directly with RPA to block its 
interaction with single-stranded DNA and most importantly 
these inhibitors do not bind directly with DNA. The system-
atic SAR exploration had revealed that a heteroaromatic ring 
or reasonably a larger lipophilic biphenyl ring at the Ring A 
and an extension of the terminal carboxylic acid side chain are 
well tolerated. Particularly, the introduction of morpholino 
group at the terminal alkyl carboxylic acid side chain resulted 
in the enhanced potency, solubility and cellular up-take. Com-
pound 43, 45 and 46 represent excellent lead compounds with 
drug-like properties suitable for future cellular and in vivo 
studies. These efforts will be addressed in a subsequent man-
uscript.  
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